EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 3.0

For Advanced Oesophageal Squamous Cell Carcinoma, PD-1 Antibody Combined with Chemotherapy Improves Progression-Free Survival Compared with Monotherapy or Chemotherapy Alone as First-Line Treatment: A Retrospective Study with Prognostic Biomarker Analysis

Feng Ju, Yong Ji

Drug Design, Development and Therapy · 2026

DOI: 10.2147/dddt.s600971 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Drug Design, Development and Therapy, 2026. Verfasst von Feng Ju und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Affairs Management, Jingjiang People's Hospital Affiliated to Yangzhou University, Jingjiang, Jiangsu, 214504, People's …. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Antineoplastic Combined Chemotherapy Protocols, Programmed Cell Death 1 Receptor. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaAntineoplastic Combined Chemotherapy ProtocolsProgrammed Cell Death 1 ReceptorAntibodies, Monoclonal, HumanizedHumansRetrospective StudiesMaleFemaleBiomarkers, TumorProgression-Free SurvivalPrognosisMiddle AgedAgedAdult

Stichwörter der Autor:innen

oesophageal squamous cell carcinomaprognosisprogrammed cell death 1 receptortherapy

Substanzen

Biomarkers, TumorProgrammed Cell Death 1 ReceptorAntibodies, Monoclonal, HumanizedcamrelizumabPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Pharmaceutical Affairs Management, Jingjiang People's Hospital Affiliated to Yangzhou University, Jingjiang, Jiangsu, 214504, People's Republic of China.
  • Department of General Surgery, Jingjiang People's Hospital Affiliated to Yangzhou University, Jingjiang, Jiangsu, 214504, People's Republic of China.

Zitieren

APA

Ju, F., & Ji, Y. (2026). For Advanced Oesophageal Squamous Cell Carcinoma, PD-1 Antibody Combined with Chemotherapy Improves Progression-Free Survival Compared with Monotherapy or Chemotherapy Alone as First-Line Treatment: A Retrospective Study with Prognostic Biomarker Analysis. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s600971

Vancouver

Ju F, Ji Y. For Advanced Oesophageal Squamous Cell Carcinoma, PD-1 Antibody Combined with Chemotherapy Improves Progression-Free Survival Compared with Monotherapy or Chemotherapy Alone as First-Line Treatment: A Retrospective Study with Prognostic Biomarker Analysis. Drug Design, Development and Therapy. 2026. doi:10.2147/dddt.s600971

BibTeX
@article{Ju2026,
  author = {Ju, Feng and Ji, Yong},
  title = {For Advanced Oesophageal Squamous Cell Carcinoma, PD-1 Antibody Combined with Chemotherapy Improves Progression-Free Survival Compared with Monotherapy or Chemotherapy Alone as First-Line Treatment: A Retrospective Study with Prognostic Biomarker Analysis},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  doi = {10.2147/dddt.s600971}
}
Kostenlos starten →